Freeline Shareholders Approve Acquisition by Syncona
LONDON, Feb. 12, 2024 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (“Freeline”) and Syncona Ltd (“Syncona”) today announced…
Pharmaceuticals, Biotechnology and Life Sciences
LONDON, Feb. 12, 2024 (GLOBE NEWSWIRE) — Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (“Freeline”) and Syncona Ltd (“Syncona”) today announced…
NEW YORK, Feb. 09, 2024 (GLOBE NEWSWIRE) — Better Choice Company (NYSE: BTTR) (“Better Choice” or “the Company”), a pet…
WATERTOWN, Mass., Feb. 09, 2024 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,…
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage…
– Year-over-year revenue increased 114% for the fiscal second quarter and 337% for the six-months ending December 31, 2023 –…
PharmAla will consult on GMP Drug Product and Regulatory Development for Red Light HollandVANCOUVER, British Columbia, Feb. 09, 2024 (GLOBE…
– BLA submission supported by results from Phase 2/3 clinical trial and outcomes of real-world use of the HAV under…
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage…
BOSTON & LONDON, Feb. 09, 2024 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA) announced that data from an additional…
OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients…